Abstract 1488P
Background
Platinum-based chemotherapy (CT) with PDL-1 blockade is the standard of care in ES-SCLC. Relevant randomized controlled trials were restricted to patients(pts) with ECOG PS 0-1 at initiation of therapy. These trials also prohibited use of consolidation radiotherapy (RT) or salvage RT to treat of oligo-progression. We aimed to evaluate outcomes in pts with poor ECOG PS and those receiving non-palliative RT, as well as the prevalence and outcomes of durvalumab (DRV) beyond progression.
Methods
A retrospective data collection including pts from 11 centers in four countries. Primary endpoints were overall survival (OS) and duration of treatment (DOT) in the overall population and in the subgroup of pts with ECOG ≥2. Secondary endpoints included safety, OS and DOT in pts treated with non-palliative RT as well as the use of ICI beyond progression.
Results
A total of 100 pts received durvalumab with CT for ES-SCLC. 68% were male, median age was 65 years (range 39-83) and 23% had an ECOG ≥2. Overall, 29% of patients received RT during durvalumab treatment, 22% as salvage/consolidation. Fifteen pts (15%) were treated with DRV beyond progression for a median of 4 cycles (range 1-14). Median OS in the entire cohort was 11.5mo, 13.3mo in pts with ECOG 0-1 and 10.3mo in pts with ECOG ≥2 (p=0.028). Median DOT in the entire cohort was 4.5mo and 4.2 in pts with ECOG ≥2 (p=0.006). Pts receiving non-palliative RT showed a trend toward improved OS and DOT (Table). Eight pts (8%) discontinued DRV due to immune-related adverse events. Table: 1488P
mDOT and mOS in pts receiving non-palliative RT
| All patients | Pts with consolidation/salvage RT | P-VALUE | |
| mDOT with durvalumab (months) | 4.5 | 5.9 | 0.056 |
| mOS (months) | 11.5 | 14.7 | 0.190 |
Conclusions
Treatment with CT and DRV is safe and effective in pts with ES-SCLC with ECOG PS ≥2 as well as in pts receiving concomitant radiotherapy. Treatment discontinuation rate due to toxicity was comparable to that reported in the CASPIAN study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21